There hasn't been a genuinely new kind of blood-pressure drug in a generation
The core idea stands, but key numbers or details have changed.
TaughtHigh blood pressure is treated with the same handful of drug families your parents took: diuretics, ACE inhibitors, ARBs, calcium-channel blockers, beta-blockers. Nothing mechanistically new has arrived in decades, and for resistant patients the cupboard is bare.
NowOn 18 May 2026 the FDA approved baxdrostat (Baxfendy), an aldosterone synthase inhibitor, the first mechanistically new class of blood-pressure drug in decades. It blocks the enzyme that makes aldosterone, a hormone that drives hard-to-treat hypertension.
What actually happened
Aldosterone raises blood pressure by making the body hold onto salt and water, and in many people with resistant hypertension it is quietly the culprit. Older drugs blocked aldosterone's receptor; baxdrostat goes upstream and shuts down the enzyme that produces the hormone in the first place. In the BaxHTN trial it lowered systolic pressure by roughly 9–10 mmHg on top of existing medications, in patients whose pressure had refused to come down.
The honest scale: this is an add-on for people already on other drugs, not a replacement for the cheap generics that work fine for most, and long-term outcome data will take years. Calling it 'updated' rather than 'disproved' is deliberate; the old drugs were never wrong, the toolbox just had a genuinely empty shelf. What changed is that the shelf is no longer empty for the first time in a generation.
Newsletter
Get new weekly revisions
Sources
Who was taught this
Still standard through 2026, so anyone who finished school between 1950 and 2026 learned the earlier version.